Multimodality imaging of CXCR4 in cancer: Current status towards clinical translation

Current Molecular Medicine

Volumn 13, Issue 10, 2013, Pages 1538-1548

  Nayak, T R ^a   Hong, H ^a   Zhang, Y ^b   Cai, W ^a,b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Cancer; Chemokine; Chemokine receptor; CXCR4; Metastasis; Molecular imaging; Positron emission tomography (PET)

Indexed keywords

8 [(4 AMINOBUTYL) (2 BENZIMIDAZOLYLMETHYL) AMINO] 1, 2, 3, 4 TETRAHYDROQUINOLINE; 8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; KRH 1636; N [1, 4, 8, 11 TETRAAZACYCLOTETRADECANYL 1, 4 PHENYLENEBIS (METHYLENE) ] 2 (AMINOMETHYL) PYRIDINE; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

BIOLUMINESCENCE; CONFOCAL MICROSCOPY; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METASTASIS; MOLECULAR IMAGING; NEOPLASM; NONHUMAN; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR GROWTH;

ANIMALS; HUMANS; MULTIMODAL IMAGING; NEOPLASMS; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84889039588     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524013666131111121325     Document Type: Review

References (89)

1. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6.
2. Murphy PM. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev 2002; 54: 227-9.
3. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 2007; 25: 787-820.
4. Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol 2002; 42: 469-99.
5. Bacon K, Baggiolini M, Broxmeyer H, et al. Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res 2002; 22: 1067-8.
6. Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008; 267: 226-44.
7. Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost 2007; 97: 714-21.
8. Iwamoto T, Okamoto H, Toyama Y, Momohara S. Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J 2008; 275: 4448-55.
9. Mines M, Ding Y, Fan GH. The many roles of chemokine receptors in neurodegenerative disorders: emerging new therapeutical strategies. Curr Med Chem 2007; 14: 2456-70.
10. De Clercq E. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mol Pharmacol 2000; 57: 833-9.
11. Fujii N, Nakashima H, Tamamura H. The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opin Investig Drugs 2003; 12: 185-95.
12. Kang H, Watkins G, Douglas-Jones A, Mansel RE, Jiang WG. The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast 2005; 14: 360-7.
13. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004; 14: 171-9.
14. Kulbe H, Levinson NR, Balkwill F, Wilson JL. The chemokine network in cancer-much more than directing cell movement. Int J Dev Biol 2004; 48: 489-96.
15. Yoon Y, Liang Z, Zhang X, et al. CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res 2007; 67: 7518-24.
16. Li JK, Yu L, Shen Y, et al. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro. World J Gastroenterol 2008; 14: 2308-13.
17. Zeng Z, Samudio IJ, Munsell M, et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 2006; 5: 3113-21.
18. Oda Y, Tateishi N, Matono H, et al. Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma. Int J Cancer 2009; 124: 1852-9.
19. 18F-based radiotracers. Am J Nucl Med Mol Imaging 2012; 2: 55-76.
20. 18F-FDG PET in sarcoma treatment response imaging. Am J Nucl Med Mol Imaging 2011; 1: 47-53.
21. Hong H, Zhang Y, Sun J, Cai W. Positron emission tomography imaging of prostate cancer. Amino Acids 2009; 39: 11-27.
22. Hong H, Zhang Y, Sun J, Cai W. Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today 2009; 4: 399-413.
23. 11C-acetate. Am J Nucl Med Mol Imaging 2012; 2: 33-47.
24. Vach W, Høilund-Carlsen PF, Fischer BM, Gerke O, Weber W. How to study optimal timing of PET/CT for monitoring of cancer treatment. Am J Nucl Med Mol Imaging 2011; 1: 54-62.
25. Wang RE, Niu Y, Wu H, Amin MN, Cai J. Development of NGR peptide-based agents for tumor imaging. Am J Nucl Med Mol Imaging 2011; 1: 36-46.
26. Hong H, Yang Y, Zhang Y, Cai W. Non-invasive imaging of human embryonic stem cells. Curr Pharm Biotechnol 2010; 11: 685-92.
27. Cai W, Zhang Y, Kamp TJ. Imaging of induced pluripotent stem cells: from cellular reprogramming to transplantation. Am J Nucl Med Mol Imaging 2011; 1: 18-28.
28. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009; 23: 43-52.
29. Baribaud F, Edwards TG, Sharron M, et al. Antigenically distinct conformations of CXCR4. J Virol 2001; 75: 8957-67.
30. Wong D, Korz W. Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin Cancer Res 2008; 14: 7975-80.
31. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16: 2927-31.
32. Masuda M, Nakashima H, Ueda T, et al. A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II). Biochem Biophys Res Commun 1992; 189: 845-50.
33. Tamamura H, Xu Y, Hattori T, et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun 1998; 253: 877-82.
34. Tchou I, Misery L, Sabido O, et al. Functional HIV CXCR4 coreceptor on human epithelial Langerhans cells and infection by HIV strain X4. J Leukoc Biol 2001; 70: 313-21.
35. Demmer O, Gourni E, Schumacher U, Kessler H, Wester HJ. PET imaging of CXCR4 receptors in cancer by a new optimized ligand. Chem Med Chem 2011; 6: 1789-91.
36. De Clercq E, Yamamoto N, Pauwels R, et al. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci USA 1992; 89: 5286-90.
37. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003; 2: 581-7.
38. 64Cu-AMD3100-a novel imaging agent for targeting chemokine receptor CXCR4. Bioorg Med Chem 2009; 17: 1486-93.
39. 64Cu]AMD3100 positron emission tomography. Cancer Res 2010; 70: 3935-44.
40. Phillips RJ, Burdick MD, Lutz M, et al. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003; 167: 1676-86.
41. Chen GS, Yu HS, Lan CC, et al. CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma. Br J Dermatol 2006; 154: 910-8.
42. Engl T, Relja B, Marian D, et al. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia 2006; 8: 290-301.
43. Bertolini F, Dell'Agnola C, Mancuso P, et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 2002; 62: 3106-12.
44. Sierra M, Yang F, Narazaki M, et al. Differential processing of stromal-derived factor-1alpha and stromalderived factor-1beta explains functional diversity. Blood 2004; 103: 2452-9.
45. Dar A, Goichberg P, Shinder V, et al. Chemokine receptor CXCR4-dependent internalization and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells. Nat Immunol 2005; 6: 1038-46.
46. Oishi S, Masuda R, Evans B, et al. Synthesis and application of fluoresceinand biotin-labeled molecular probes for the chemokine receptor CXCR4. Chembiochem 2008; 9: 1154-8.
47. Nomura W, Tanabe Y, Tsutsumi H, et al. Fluorophore labeling enables imaging and evaluation of specific CXCR4-ligand interaction at the cell membrane for fluorescencebased screening. Bioconjug Chem 2008; 19: 1917-20.
48. van den Berg NS, Buckle T, Kuil J, Wesseling J, van Leeuwen FW. Immunohistochemical detection of the CXCR4 expression in tumor tissue using the fluorescent peptide antagonist Ac-TZ14011-FITC. Transl Oncol 2011; 4: 234-40.
49. Kuil J, Steunenberg P, Chin PT, et al. Peptide-functionalized luminescent iridium complexes for lifetime imaging of CXCR4 expression. Chembiochem 2011; 12: 1897-903.
50. Nishizawa K, Nishiyama H, Oishi S, et al. Fluorescent imaging of high-grade bladder cancer using a specific antagonist for chemokine receptor CXCR4. Int J Cancer 2010; 127: 1180-7.
51. Zhang J, Fu Y, Li G, Zhao RY, Lakowicz JR. Detection of CXCR4 receptors on cell surface using a fluorescent metal nanoshell. J Biomed Opt 2011; 16: 016011.
52. Huang X, Lee S, Chen X. Design of "smart" probes for optical imaging of apoptosis. Am J Nucl Med Mol Imaging 2011; 1: 3-17.
53. Zhang Y, Hong H, Engle JW, et al. Positron emission tomography and near-infrared fluorescence imaging of vascular endothelial growth factor with dual-labeled bevacizumab. Am J Nucl Med Mol Imaging 2012; 2: 1-13.
54. Meincke M, Tiwari S, Hattermann K, Kalthoff H, Mentlein R. Near-infrared molecular imaging of tumors via chemokine receptors CXCR4 and CXCR7. Clin Exp Metastasis 2011; 28: 713-20.
55. van Dam GM, Themelis G, Crane LM, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med 2011; 17: 1315-9.
56. Liekens S, Schols D, Hatse S. CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr Pharm Des 2010; 16: 3903-20.
57. Wang J, Loberg R, Taichman RS. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev 2006; 25: 573-87.
58. Luker KE, Gupta M, Luker GD. Imaging CXCR4 signaling with firefly luciferase complementation. Anal Chem 2008; 80: 5565-73.
59. Luker KE, Gupta M, Luker GD. Imaging chemokine receptor dimerization with firefly luciferase complementation. FASEB J 2009; 23: 823-34.
60. Luker K, Gupta M, Luker G. Bioluminescent CXCL12 fusion protein for cellular studies of CXCR4 and CXCR7. Biotechniques 2009; 47: 625-32.
61. Luker KE, Mihalko LA, Schmidt BT, et al. In vivo imaging of ligand receptor binding with Gaussia luciferase complementation. Nat Med 2012; 18: 172-7.
62. Ray P, Lewin SA, Mihalko LA, et al. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4. Neoplasia 2011; 13: 1152-61.
63. Luker KE, Lewin SA, Mihalko LA, et al. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene 2012; 31: 4750-8.
64. Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med 1975; 16: 210-24.
65. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42: 1S-93S.
66. 18F-FDG PET/CT: timing for evaluation of response to therapy remains a clinical challenge. Am J Nucl Med Mol Imaging 2011; 1: 63-4.
67. 18F-FDG following cyclophosphamide and mTOR inhibition. Am J Nucl Med Mol Imaging 2012; 2: 110-21.
68. Hao G, Hajibeigi A, De León-Rodríguez LM, Öz OK, Sun X. Peptoid-based PET imaging of vascular endothelial growth factor receptor (VEGFR) expression. Am J Nucl Med Mol Imaging 2011; 1: 65-75.
69. Sephton SM, Dennler P, Leutwiler DS, et al. Synthesis, radiolabelling and in vitro and in vivo evaluation of a novel fluorinated ABP688 derivative for the PET imaging of metabotropic glutamate receptor subtype 5. Am J Nucl Med Mol Imaging 2012; 2: 14-28.
70. Donzella GA, Schols D, Lin SW, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998; 4: 72-7.
71. Gerlach LO, Skerlj RT, Bridger GJ, Schwartz TW. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 2001; 276: 14153-60.
72. 64Cu-AMD3100. Mol Imaging Biol 2012; 14: 106-14.
73. 64Cu-AMD3465. J Nucl Med 2011; 52: 986-93.
74. 18F-T140. J Nucl Med 2010; 51: 1796-804.
75. Jacobson O, Weiss ID, Szajek LP, et al. PET imaging of CXCR4 using copper-64 labeled peptide antagonist. Theranostics 2011; 1: 251-62.
76. 68Ga-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression. Bioorg Med Chem 2012; 20: 1502-10.
77. Jacobson O, Weiss ID, Szajek LP, et al. Improvement of CXCR4 tracer specificity for PET imaging. J Control Release 2012; 157: 216-23.
78. 68Ga-labeled highly specific targeted contrast agent. J Nucl Med 2011; 52: 1803-10.
79. Demmer O, Dijkgraaf I, Schumacher U, et al. Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4. J Med Chem 2011; 54: 7648-62.
80. Aparici CM, Carlson D, Nguyen N, Hawkins RA, Seo Y. Combined SPECT and multidetector CT for prostate cancer evaluations. Am J Nucl Med Mol Imaging 2012; 2: 48-54.
81. 123I-iomazenil SPECT imaging predicts cerebral hyperperfusion following endarterectomy for unilateral cervical internal carotid artery stenosis. Am J Nucl Med Mol Imaging 2012; 2: 77-87.
82. 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl Med Biol 2006; 33: 489-94.
83. 111indium labeled CXCR4 peptide antagonist. Am J Nucl Med Mol Imaging 2012; 2: 99-109.
84. Nimmagadda S, Pullambhatla M, Pomper MG. Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT. J Nucl Med 2009; 50: 1124-30.
85. 99mTc-labeled SDF-1alpha. J Nucl Med 2008; 49: 963-9.
86. Kuil J, Buckle T, Yuan H, et al. Synthesis and evaluation of a bimodal CXCR4 antagonistic peptide. Bioconjug Chem 2011; 22: 859-64.
87. Kuil J, Buckle T, Oldenburg J, et al. Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression. Mol Pharm 2011; 8: 2444-53.
88. Cai W, Hong H. Peptoid and positron emission tomography: an appealing combination. Am J Nucl Med Mol Imaging 2011; 1: 76-9.
89. 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med 2007; 48: 304-10.